Discovery is major step towards a stem cell replacement therapy for Duchenne Muscular Dystrophy
UCLA scientists have developed a new strategy to efficiently isolate, mature and transplant skeletal muscle cells created from human pluripotent stem cells, which can produce all cell types of the body. The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.
The study was published in the journal Nature Cell Biology by senior author April Pyle, associate professor of microbiology, immunology and molecular genetics and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Using the natural human development process as a guide, the researchers developed ways to mature muscle cells in the laboratory to create muscle fibers that restore dystrophin, the protein that is missing in the muscles of boys with Duchenne.
Without dystrophin, muscles degenerate and become progressively weaker. Duchenne symptoms usually begin in early childhood; patients gradually lose mobility and typically die from heart or respiratory failure around age 20. There is currently no way to reverse or cure the disease.
For years, scientists have been trying different methods that direct human pluripotent stem cells to generate skeletal muscle stem cells that can function appropriately in living muscle and regenerate dystrophin-producing muscle fibers. However, the study led by Pyle found that the current methods are inefficient; they produce immature cells that are not appropriate for modeling Duchenne in the laboratory or creating a cell replacement therapy for the disease.
“We have found that just because a skeletal muscle cell produced in the lab expresses muscle markers, doesn’t mean it is fully functional,” said Pyle. “For a stem cell therapy for Duchenne to move forward, we must have a better understanding of the cells we are generating from human pluripotent stem cells compared to the muscle stem cells found naturally in the human body and during the development process.”
By analyzing human development, the researchers found a fetal skeletal muscle cell that is extraordinarily regenerative. Upon further analysis of these fetal muscle cells two new cell surface markers called ERBB3 and NGFR were discovered; this enabled the reserchers to precisely isolate muscle cells from human tissue and separate them from various cell types created using human pluripotent stem cells.
Once they were able to isolate skeletal muscle cells using the newly identified surface markers, the research team matured those cells in the lab to create dystrophin-producing muscle fibers. The muscle fibers they created were uniformily muscle cells, but the fibers were still smaller than those found in real human muscle.
“We were missing another key component,” said Michael Hicks, lead author of the study. The skeletal muscle cells were not maturing properly, he explained. “We needed bigger, stronger muscle that also had the ability to contract.”
Once again, the team looked to the natural stages of human development for answers. Hicks discovered that a specific cell signaling pathway called TGF Beta needs to be turned off to enable generation of skeletal muscle fibers that contain the proteins that help muscles contract. Finally, the team tested their new method in a mouse model of Duchenne.
“Our long term goal is to develop a personalized cell replacement therapy using a patient’s own cells to treat boys with Duchenne,” said Hicks. “So, for this study we followed the same steps, from start to finish, that we’d follow when creating these cells for a human patient.”
First, the Duchenne patient cells were reprogrammed to become pluripotent stem cells. The researchers then removed the genetic mutation that causes Duchenne using the gene editing technology CRISPR-Cas9. Using the ERBB3 and NGFR surface markers, the skeletal muscle cells were isolated and then injected into mice at the same time a TGF Beta inhibitor was administered.
“The results were exactly what we’d hoped for,” said Pyle. “This is the first study to demonstrate that functional muscle cells can be created in a laboratory and restore dystrophin in animal models of Duchenne using the human development process as a guide.”
Further research will focus on generating skeletal muscle stem cells that can respond to continuous injury and regenerate new muscle long-term using the team’s new isolation and maturation strategy.
The Latest on: Duchenne Muscular Dystrophy
- How Target landed Lupita, the Kickstarted, Hispanic answer to Elf on the Shelf (Video) on November 12, 2018 at 9:06 am
Leslie Guzman took early retirement from P&G in 2015 after a 20-year career with the company to spend more time with her son Diego, who has Duchenne muscular dystrophy. She also took that time to crea... […]
- Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial on November 12, 2018 at 3:00 am
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ ... […]
- Global Duchenne Muscular Dystrophy (DMD) Drugs Market Size, Share & Trends (2018-2023): Analysis by Therapeutic Approach on November 9, 2018 at 7:40 am
The "Duchenne Muscular Dystrophy (DMD) Drugs Market Size, Share & Trends Analysis Report By Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy) And Segment Forecasts, 2018 ... […]
- Duchenne Muscular Dystrophy (DMD) Drugs - Worldwide Markets to 2023 - ResearchAndMarkets.com on November 9, 2018 at 4:01 am
The "Duchenne Muscular Dystrophy (DMD) Drugs Market Size, Share & Trends Analysis Report By Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy) And Segment Forecasts, 2018 - 20... […]
- The 2018 Duchenne Muscular Dystrophy Market and Competitive Landscape in Europe - ResearchAndMarkets.com on November 8, 2018 at 1:32 pm
The "Europe Duchenne Muscular Dystrophy Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. This latest research provides comprehensive insights into D... […]
- Parent Project Muscular Dystrophy Designates Children's Hospital of Wisconsin a Certified Duchenne Care Center on November 6, 2018 at 7:22 am
HACKENSACK, N.J., Nov. 6, 2018 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), named the Neuromuscul... […]
- Cornhole tournament hits mark for Muscular Dystrophy Association on November 6, 2018 at 12:58 am
Julie Harris, mother of Brandon Harris, 18, of Gordon, who has Duchenne muscular dystrophy, which is a condition characterized by progressive muscle degeneration and weakness, and Jess Florkowski, mot... […]
- GR .1K race to end Duchenne Muscular Dystrophy on November 3, 2018 at 4:41 am
GRAND RAPIDS, Mich. -- The race is one of the shortest in the country. Coming in at 384 feet, or 0.1K, the race has gained popularity in its efforts to end Duchenne muscular dystrophy. In its eighth y... […]
- Decent: Muscular dystrophy not holding back Naperville teen or his parents, who have raised more than $1.5M for research on November 2, 2018 at 9:16 am
The family was launching its first fundraiser, named for their son Ryan, for Duchenne Muscular Dystrophy research. With no experience other than the ability to throw a great party, Marty and Geri Karl... […]
- Muscular Dystrophy 24 hour Shear-A-Thon on November 2, 2018 at 1:56 am
The pair said they had been long time friends with the Gillin family whose sons, Chris and Aaron, have Duchenne Muscular Dystrophy. Aaron Gillin died last year at the age of 24 but his older brother C... […]
via Google News and Bing News